Amicus Therapeutics

PA - PhiladelphiaBiotechnology1 H-1B visas (FY2023)

Focus: Amicus Therapeutics is a Philadelphia-based biotech focused on rare lysosomal storage diseases and cardiovascular conditions using small molecule therapies. The company is anchored by GALAFOLD, a peak commercial product generating $35M in annual Part D spending.

Rare Diseases Cardiovascular

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Open Jobs

About Amicus Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Amicus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

GALAFOLD

Fabry Disease

$35M Part D

Peak15.7yr

Flagship product driving 98% of company revenue with exclusive patent protection for 18+ years; mechanism stabilizes deficient alpha-galactosidase A protein in amenable GLA variants.

Help build intelligence for Amicus Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong rare disease focus with proven commercial success: GALAFOLD is at peak lifecycle with patent protection until 2042-01-11, providing revenue stability.
Robust Phase 3 pipeline with 7 programs in late-stage development across Pompe disease, Fabry disease, and emerging indications like epidermolysis bullosa.
Clear scientific focus on lysosomal biology and protein stabilization, offering deep technical expertise in a specialized therapeutic area.

Watch Out For

Extreme revenue concentration (98% from single product) creates significant commercial risk if GALAFOLD faces competition or regulatory setbacks post-2038.
Zero active job openings at time of assessment suggests limited hiring momentum or organizational contraction.
Clinical pipeline heavily tilted toward Pompe disease (4 programs) risks overdependence on single indication success.

Generated by Claude from Amicus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

POMBILITI

Pompe Disease

Growth

Growth-stage biologic approved for glycogen storage disease Type II; novel dual-targeting approach with miglustat co-formulation to stabilize enzyme in circulation.

OPFOLDA

Pompe Disease

Growth12.3yr

Oral small molecule in growth phase targeting Pompe disease with patent life extending to 2038; complements POMBILITI in company's multi-pronged Pompe strategy.

MIGLUSTAT

Glycogen Storage Diseases

$542K Part D

Post-LOE

Legacy product post-loss of exclusivity; glucosylceramide synthase inhibitor generating minimal revenue but used as adjunctive therapy in pipeline programs.

Pipeline & Clinical Trials

Survey

Epidermolysis Bullosa

N/A

Clinical Trials (1)

NCT03158662Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

N/A

dry blood test

Fabry Disease

N/A

Clinical Trials (1)

NCT04184986Screening of Fabry Disease in Patients With GI Symptoms

N/A

Noninterventional characterization of patients expectations and preferences regarding their treatment

Fabry Disease

N/A

Clinical Trials (1)

NCT04043273Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences

N/A

Observation

Pompe Disease

N/A

Clinical Trials (1)

NCT00515398A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease

N/A

Blood sample

Gaucher Disease

N/A

Clinical Trials (1)

NCT00351156Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

N/A

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Late-onset Pompe Disease

N/A

Clinical Trials (1)

NCT03347253STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

N/A

This is a non-interventional study

Fabry Disease

N/A

Clinical Trials (1)

NCT04804566Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

N/A

Enzyme Replacement Therapy

Fabry Disease

N/A

Clinical Trials (1)

NCT04281537A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

N/A

Diet and Exercise

Pompe Disease

N/A

Clinical Trials (1)

NCT02363153Diet and Exercise in Pompe Disease

N/A

Real World Evidence Study of Danish Fabry Patients

Fabry Disease

N/A

Clinical Trials (1)

NCT06303466Real World Evidence Study of Danish Fabry Patients

N/A

BNP blood sample test

Hypertrophic Cardiomyopathy

N/A

Clinical Trials (1)

NCT04129905Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies

N/A

GR181413A/AT1001 solution

Fabry Disease

Phase 1

Clinical Trials (1)

NCT01853852A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

Phase 1

Zavesca® Prescription

Pompe Disease

Phase 1

Clinical Trials (1)

NCT02185651A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction

Phase 1

AT2101

Type 1 Gaucher Disease

Phase 1

Clinical Trials (1)

NCT00875160A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Phase 1

duvoglustat

Pompe Disease

Phase 2

Clinical Trials (2)

NCT00688597Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

Phase 2

NCT01380743Drug-drug Interaction Study

Phase 2

afegostat

Gaucher Disease, Type 1

Phase 2

Clinical Trials (3)

NCT00446550A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease

Phase 2

NCT00813865A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

amisulpride

Nausea and Vomiting, Postoperative

Phase 2/3

AT2221

Pompe Disease

Phase 3

Clinical Trials (4)

NCT04138277A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Phase 3

NCT02675465First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

miglustat

Pompe Disease

Phase 3

cipaglucosidase alfa

Pompe Disease

Phase 3

Clinical Trials (4)

NCT03729362A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

Phase 3

NCT04808505A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

migalastat

Fabry Disease

Phase 3

Clinical Trials (5)

NCT04020055A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Phase 3

NCT01218659Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

SD-101

Epidermolysis Bullosa

Phase 3

Clinical Trials (4)

NCT02384460ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Phase 3

NCT02670330Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 approved products, 55 clinical trials

Top TAs: Rare Diseases, Cardiovascular

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Growth2 (50%)

Peak1 (25%)

Post-LOE1 (25%)

4 total products

Therapeutic Area Focus

Rare Diseases

4 marketed48 pipeline

Cardiovascular

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Private Funding (SEC Form D)

Dec 2013

Jul 2012

NCT00433147A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

Phase 2

NCT04327973Expanded Access for ATB200/AT2221 for the Treatment of IOPD

N/A

NCT03911505ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Phase 3

NCT04049760Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Phase 3

NCT02090283Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Phase 2

Amicus Therapeutics

About Amicus Therapeutics

Why Work Here

Key Products

Watch Out For

Products & Portfolio (3)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Private Funding (SEC Form D)